



CELL & GENE THERAPY INSIGHTS

Your content marketing partner for life sciences

MEDIA KIT 2023





Your content
marketing
partner for life
sciences

INDEX

▶ About	3
▶ User demographics	7
▶ Who do we work with?	14
▶ Opportunities	18
▶ Webinars	19
▶ Expert roundtables	19
▶ Articles	19
▶ Interviews & podcasts	19
▶ Infographics	19
▶ What can we do for you?	5
▶ Editorial calendar	11
▶ Video presentations	22
▶ Scientific illustrations	25
▶ eBlasts	26
▶ Our other publications	27

ABOUT

Cell & Gene Therapy Insights

Cell and Gene Therapy Insights is an online, peer-reviewed, open access journal with a translational focus. Key scientific, regulatory, business and manufacturing challenges and advances are addressed through publication of original research, reviews, commentary articles, clinical trial reports and much more.

All content is available free of charge, and the written material is complemented by engaging formats such as webinars, infographics, animations, video and podcasts.

An online,
peer-reviewed,
open access journal
with a translational
focus

Senior Editor: Prof. Chris Ma...

**CELL & GENE
THERAPY
INSIGHTS**



Is it important for **your company to demonstrate its capabilities** to scientists and/or business leaders making key technology platform decisions at an early stage in a product's development?

Do you need to **generate qualified leads** from companies involved in viral vector manufacture?

Are you looking to **provide educational materials** to individuals focused on analytical, process or clinical development?

Cell & Gene Therapy Insights provides a unique online content marketing and lead-generation opportunity:

- ▶ **Active engagement of key stakeholders** from across the global community all year round
- ▶ The chance to **target organizations at varying stages of the R&D pipeline:** Universities, spin-outs, biotechs, pharma, hospitals, investors and analysts
- ▶ An **alternative to the ever-more expensive conference market**
- ▶ A means by which you can **access the people making the key new discoveries**, those individuals driving the delivery of safe and effective therapies to patients, and those manufacturing the cell and gene therapies of the future



Cell & Gene
Therapy Insights
provides a unique online
content marketing and
lead-generation
opportunity

WHAT CAN WE DO FOR YOU?

We can:

- ▶ Provide support in the **development of your content marketing strategy** and tactics for this sector, partnering with you in the development of your annual marketing plans
- ▶ Work closely with you to **create quality written, video and audio content** of high value to your target audience
- ▶ Offer you opportunities to **re-purpose scientific and educational content** you have already developed and make it available to a global audience
- ▶ **Raise your company's profile**, demonstrate your capabilities, and enhance your reputation as a thought-leader in the sector
- ▶ Play a key role in your **lead-generation activities**
- ▶ Ensure your leading scientists are seen as **Subject Matter Experts** throughout your target market
- ▶ **Create written content from video or audio**, ideal for increasing the reach, longevity and searchability of your data and other technical information

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

We can partner with you to develop high quality content to demonstrate your thought-leadership:


- ▶ Your own special focus issue or ebook on the topic of your choice
- ▶ Client case studies, interviews and co-presentations
- ▶ Peer reviewed articles, as well as editorials and commentaries
- ▶ Video presentations and roundtables
- ▶ Podcasts
- ▶ Infographics and animations
- ▶ Webinars, both live and on demand



USER DEMOGRAPHICS

Data by sector

- ▶ **Biotech companies**, including those at a relatively early stage of development. Our research shows that these earlier stage companies attend fewer industry conferences than those at a later stage, so Cell & Gene Therapy Insights offers an unparalleled opportunity to target this particular audience
- ▶ **Prolific academic institutions and research hospitals**, in particular those that generate spin-outs based on cell and gene therapy candidates and technologies
- ▶ **Pharmaceutical companies and large biotechs** with a major or growing focus on cell and gene therapies
- ▶ **Government-funded organizations** (such as NIH) and NGOs
- ▶ **Investors and analysts**
- ▶ **Solution and service providers**




31%
Biotech




30%
Academic/
Hospital



13%
Pharma/
Large Biotech



6%
Government/
NGO



2%
Investor/
Analyst




21%
Solution/Service
Provider

We
currently
have 27,000
registered
users


Cell & Gene Therapy Insights has a translational focus, featuring content of value to individuals along the R&D pipeline.

Data by interest area & seniority

- ▶ Discovery and basic research
- ▶ Preclinical development and translational R&D
- ▶ Clinical research
- ▶ Product development, process development, operations, logistics and manufacture
- ▶ Regulatory affairs, QA/QC and validation
- ▶ Business development, corporate management and licensing



Data by interest area & seniority continued




Data by location

▶ **54%**
North America

▶ **34%**
Europe

▶ **9%**
Asia and Australia

▶ **3%**
Rest of World



EDITORIAL CALENDAR



Spotlights

Each monthly Spotlight focuses BioInsights members' attention on a particular topic or technology area. We leverage an array of formats to provide a comprehensive update on the key trends, challenges and breakthroughs in a given field: Independently peer reviewed Expert Insights, Opinion pieces, Interviews, Webinars, Podcasts, FastFacts videos and more...



Channel Editions

Channels allow us to zoom right in on specific aspects that are of special interest to BioInsights members, including vector manufacture (viral and non-viral), analytics, and supply chain.



Reports

Our Reports provide up-to-the-minute news and opinion on the stories and breakthroughs of the day from right across the cell and gene therapy field.

Covering everything from R&D innovation to regulatory affairs, and from business/commercial strategy to clinical trends.



Podcast series

We select a key issue or challenge, then invite a range of stakeholders to proffer their opinions and share related learnings via the ever-popular, easy-to-consume podcast format.

You are able to sponsor any of the spotlights and focus issues and/or select an issue for the content we develop together. We also feature a number of topic-specific channels on our website:

- Vectors
- Manufacturing
- Supply Chain
- Analytical
- Regulatory
- Translational & Clinical Research

2023 Editorial Calendar

	JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE
Journal Spotlights 		Preclinical & translational R&D	Cell therapy materials & upstream processing/ analytics	Vector bioprocessing & raw materials	Gene delivery platform evolution Part 1: Viral	Gene delivery platform evolution Part 2: Non-viral
Channel Editions Published quarterly: -Vector - Supply Chain - Analytics		VECTOR: Scalability	SUPPLY CHAIN: Innovation in cryopreservation and cold chain management		SUPPLY CHAIN: Optimizing materials and consumables sourcing strategy through scale-up/-out	VECTOR: Upstream Processing
Channel Newsletters 		Manufacturing Vector Analytics	Manufacturing Vector	Manufacturing Vector Supply chain Analytics	Manufacturing Vector	Manufacturing Vector
Cell and Gene Therapy Update		Cell and Gene Therapy update		Cell and Gene Therapy update		Cell and Gene Therapy update
	JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER
Journal Spotlights 	Gene therapy CMC & analytics	New horizons in immunotherapy	Scale-up/-out of cell & gene therapy manufacturing	Fulfilling the potential of gene editing: at the tipping point RNA vaccines and therapeutics (shared with Vaccine Insights)	Cell therapy downstream processing & CMC	Clinical trends of 2023/ tools of tomorrow
Channel Editions Published quarterly: -Vector - Supply Chain - Analytics		SUPPLY CHAIN: Digitizing the cell and gene therapy supply chain		VECTOR: Downstream bioprocessing	SUPPLY CHAIN: Navigating the final mile: how to ensure the healthcare sector are prepared to deliver the commercial cell and gene therapies of tomorrow to patients?	VECTOR: Characterization and validation
Channel Newsletters 	Manufacturing Vector Supply chain Analytics	Manufacturing Vector	Manufacturing Vector	Manufacturing Vector Supply chain Analytics	Manufacturing Vector	Manufacturing Vector Supply chain
Cell and Gene Therapy Update		Cell and Gene Therapy update		Cell and Gene Therapy update		Cell and Gene Therapy update

WHO DO WE WORK WITH?



- ▶ AGC Biologics
- ▶ Aldevron
- ▶ Alfa Wassermann
- ▶ Alphalyse
- ▶ AmerisourceBergen
- ▶ Aseptic Technologies SA
- ▶ Batavia Biosciences
- ▶ Be The Match BioTherapies
- ▶ Beckman Coulter
- ▶ Berkeley Lights
- ▶ BIA Separations
- ▶ BioIVT
- ▶ BioLife Solutions
- ▶ bioMerieux
- ▶ BioQuell
- ▶ Bio-Rad
- ▶ Bio-Techne
- ▶ CellGenix GmbH
- ▶ Cellular Highways
- ▶ Center for Breakthrough Medicines
- ▶ Cevac Pharmaceuticals
- ▶ Charles River Laboratories
- ▶ Charter Medical
- ▶ Corning Life Sciences
- ▶ CPC
- ▶ Cytiva
- ▶ Eppendorf
- ▶ Eureka Biotechnology
- ▶ Eurofins Panlabs
- ▶ Eurofins VRL
- ▶ Fresenius Kabi
- ▶ FUJIFILM Irvine Scientific
- ▶ Gyros Protein Technologies
- ▶ Horizon Discovery
- ▶ Invetech
- ▶ Isolere Bio
- ▶ Lonza
- ▶ Malvern Panalytical
- ▶ Maxcyte
- ▶ Microfluidx
- ▶ MilliporeSigma
- ▶ Miltenyi Biotec
- ▶ Mirus Bio
- ▶ Mogrify Ltd
- ▶ Ncardia
- ▶ Nexcelom Biosciences
- ▶ Oxford BioMedica
- ▶ OXGENE
- ▶ Pall Biotech
- ▶ Perkin Elmer
- ▶ Polyplus-transfection
- ▶ Precision Nanosystems
- ▶ Qiagen
- ▶ Quick Pharma Logistics
- ▶ Reading Scientific Services
- ▶ Repligen
- ▶ Roche Custom Biotech
- ▶ RoosterBio
- ▶ Sartorius
- ▶ SCIEX
- ▶ Sexton Biotechnologies
- ▶ Single Use Support
- ▶ Sony Biotechnology
- ▶ Terumo BCT
- ▶ Thermo Fisher Scientific
- ▶ TouchLight
- ▶ Vineti, Inc
- ▶ Vironova AB
- ▶ VivaBioCell SpA
- ▶ VIVEbiotech

Contact Nicola McCall at n.mccall@insights.bio to discuss thought leadership and lead-generation opportunities

OPPORTUNITIES

We offer a broad range of options to help you reach your target audience, any of which can be tailored to match your current marketing and business development priorities. These include interviews, expert roundtables, podcasts, webinars, articles, video presentations, infographics, eblasts and more.

Any of our options can be tailored to match your current marketing and business development priorities.



WEBINARS


Presenting a webinar with *Cell & Gene Therapy Insights* gives you an efficient and cost-effective way to:

- ▶ Generate qualified leads from amongst the global cell and gene therapy community
- ▶ Demonstrate your company's expertise and capabilities
- ▶ Stimulate discussion around a topic of significant importance to your customers
- ▶ Educate individuals on crucial regulatory, scientific or technical issues
- ▶ Make a noise around a new product or service offering launch

Webinars can stand alone or can be included in a Spotlight, depending on the topic and timing fit.

Our
2023
webinar
schedule is filling up
fast.

Contact n.mccall@insights.bio
to discuss options & availability.



Presenting a webinar with us is an efficient and cost-effective way to generate qualified leads.

Our webinar packages include:

- ▶ As much support as you need in terms of topic selection and agenda development, format selection, and speaker panel identification and invitation
- ▶ Full hosting and technical support, including planning calls with panellists and rehearsals as needed
- ▶ A comprehensive promotional plan, including multiple email shots to our database, website and newsletter marketing, and social media
- ▶ A moderator from our editorial team to ensure the webinar runs smoothly on the day
- ▶ Registration and attendee lists for the webinar
- ▶ A report on the questions submitted during the live webinar so you can follow up directly with individuals afterwards and continue the discussion
- ▶ Hosting of the webinar recording on an indefinite basis with ongoing lead generation
- ▶ Webinar recording provided to you for hosting on your own site
- ▶ The option for us to publish an article based on the transcript of the webinar, repurposing your presentation into written format and making it search engine friendly

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

Examples of previous webinars for our clients:

Panel-style webinar with accompanying transcript-based article for Thermo Fisher Scientific

Feb 3 2022 | ON DEMAND | The digital revolution: Technological innovations to enable automation in cell therapy manufacturing | Sponsor: Thermo Fisher Scientific

CELL & GENE THERAPY INSIGHTS

INNOVATOR INSIGHT

The digital revolution: technological innovations to enable automation in cell therapy manufacturing

Sean Chang, Bruce Grosswald & Kish Roy

Cell therapy manufacturing solutions typically involve complex tasks, making extensive human intervention a requirement. This can greatly hinder overall production, limiting the number of doses that can be produced. Thermo Fisher's new digital manufacturing solutions, such as the digital manufacturing solutions for cell therapy manufacturing, can help you overcome these challenges. This article explores the benefits of digital manufacturing solutions for cell therapy manufacturing, including the ability to scale production, improve quality, and reduce costs. It also discusses the challenges of digital manufacturing and how to overcome them. For more information, visit www.thermofisher.com.

Get a Gene Therapy Insight 2022, 800.355.3535 | 001-310-999-9999

355

Presentation-style webinar with Q&A for Lonza

May 5 2022 | ON DEMAND | Process development excellence to de-risk and accelerate commercialization of cell and gene therapies | Sponsor: Lonza

Watch now

SPEAKERS

Behnam Baghbaderani
Global Head, Process Development,
Emerging Technologies at Lonza Pharma & Biotech

Live30 webinar:
a 30 minute webinar focused on new technologies and their applications for OXGENE

Feb 10 2022 | ON DEMAND | TESSA technology: A new era for AAV manufacture | Sponsor: OXGENE

Live 30

Watch now

SPEAKERS


Ryan Cawood
Chief Scientific Officer at OXGENE

You can view all of our on-demand webinars here.

EXPERT ROUNDTABLES

On-demand video expert roundtables provide powerful tools for you to generate qualified leads and/or position your thought-leader(s) at the heart of the debate around a topic of key importance to your company. Our editorial team works closely with you to identify over-arching topics and discussion points, and to convene a panel of KOLs. We then liaise with the panel to define the final list of questions for discussion, video and edit the roundtable itself, and then produce a full article based on the transcript.

Video roundtable examples:



Video




Article

Embracing transformation: how big data, AI and digitization are changing cell and gene therapy manufacture (for Cytiva)



Video & article



Poster summarising key learning points


Strategies for scaling up and out in gene therapy manufacturing: addressing AAV's growing pains (for Corning)

ARTICLES

Free access publication of submitted articles remains the gold standard for sharing data with scientists across the sector.

Our sponsored article publication package includes full peer review, a license for you to reproduce the article on your own website, and a comprehensive 2-month promotional package to maximise readership.

Examples of articles for our clients:



VECTOR BIOPROCESSING


Clarification of recombinant adeno-associated virus (rAAV) adherent culture

Cell & Gene Therapy Insights 2022; 8(3): 483–493
DOI: 10.18609/cgti.2022.070
PUBLISHED: 30 APRIL 2022

RESEARCH ARTICLE

Rajeshwar Chinnawar, Nicholas Marchand

In recent years the cell and gene therapy industries have been rapidly expanding, with two adeno-associated virus (AAV) and lentivirus. With clinical success comes the need to develop processes. As both of these vectors are produced in cells, the first step in their purification many technologies traditionally used for cell culture clarification but given the projected consumables a combination of depth and membrane filtration is a logical fit for batch pro-




CELL & GENE THERAPY INSIGHTS

FIGURE 2
Comparison of clarification methods against AAV recovery

TABLE 1
Comparison of clarification methods against AAV recovery

TABLE 2
Comparison of clarification methods against AAV recovery

488 DOI: 10.18609/cgti.2022.070



ANALYTICS: Enhancing accuracy & throughput


Accelerating AAV capsid analysis using a new multi-capillary platform

Cell & Gene Therapy Insights 2022; 8(2): 231–240
DOI: 10.18609/cgti.2022.029
PUBLISHED: 16 MARCH 2022

INNOVATOR INSIGHT

Susan Darling

Adeno-associated viral (AAV) vectors, while offering numerous advantages over other viruses (non-pathogenic, low immunogenicity, and can readily enter a variety of cell types), are highly complex molecules that present significant manufacturing challenges. There are a large number of serotypes to choose from, and the need to implement transfection processes that afford high yields of capsids containing the gene of interest and purification hurdles to overcome. From an analytical perspective, samples are getting more complex, more numerous, and require more complex analytical methods that involve complex method set ups, but results are needed in less time. Despite these challenges, developers of gene therapies must be able to understand the molecular liabilities of AAV vectors as soon as possible in the




AAV/PSI: Enhancing accuracy & throughput

FIGURE 1
Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform

TABLE 1
Comparison of clarification methods against AAV recovery

TABLE 2
Comparison of clarification methods against AAV recovery

231 DOI: 10.18609/cgti.2022.029



CELL THERAPY CMC AND QUALITY CONTROL


Characterization of a novel high-throughput, high-speed based image cytometric cell counting method

Cell & Gene Therapy Insights 2021; 7(4): 427–447
DOI: 10.18609/cgti.2021.070
PUBLISHED: 14 MAY 2021

RESEARCH ARTICLE

Jordan Bell, Yongyang Huang, Henry Qazi, Dmitry Kuksin, Jean Qiu, Bo Lin, Leo L.

Bioprocessing applications for cells and biologics have dramatically increased the number immunotherapy. The cell counting time is a major bottleneck for traditional counting methods, high-speed, and high-precision system. Here we characterize and demonstrate throughput cell center in bright field and fluorescence imaging modes. The system was utilized in Jurkat and CHO-S cells. We investigated the bead/cell counting com-



CELL & GENE THERAPY INSIGHTS

FIGURE 4
Comparison of cell counting methods

TABLE 1
Comparison of cell counting methods

TABLE 2
Comparison of cell counting methods

440 DOI: 10.18609/cgti.2021.070

[Clarification of recombinant adeno-associated virus \(rAAV\) & lentivirus from adherent culture \(for Pall Biotech\)](#)

[Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform \(for SCIEX\)](#)

[Characterization of a novel high-throughput, high-speed and high-precision plate-based image cytometric cell counting method \(for Nexcelom\)](#)

INTERVIEWS & PODCASTS

Interviews are a great way to raise awareness within the cell & gene therapy community, with minimal resource requirements from your team.

We can interview up to 3 of your scientists, executives, partners or clients, with the resulting video, podcast and/or written version included in an issue of the online journal.

Examples of previous interviews for our clients:

Video & written

[Stepping foot into a successful partnership to support your viral vector therapy through commercialization \(for Merck\)](#)

Podcast & written

[Precisely for CGT: automating aseptic filling for lowest volumes \(for Single Use Support\)](#)

VECTORS: Downstream Bioprocessing

Stepping foot into a successful partnership to support your viral vector therapy through commercialization

Cell & Gene Therapy Insights 2022: 7111, 1706–1710
10.18609/cgti.2021.225
PUBLISHED: 12 JANUARY 2022

Minh Hong, Marc Gaal

Charlotte Barker, Editor, Cell and Gene Therapy Insights, speaks to Minh Hong, Head of Cell and Gene Therapy Commercialization at the Life Sciences Business Sector, Merck

Minh Hong leads the commercial team for Viral Gene Therapy contract Business Sector of Merck. He is responsible for account management, business development, and commercialization of viral gene therapy products.

INTERVIEW

Q: We were the process owner, commercialization, and product development, while the client was responsible for development and manufacturing, and we were to develop the appropriate business model. The manufacturing process was an early consideration of our commercial team. It was essential to have a clear understanding of how the client's process would be implemented. This was key to the commercial process and capabilities, as well as the contract requirements for the manufacturing process.

A: A robust manufacturing process requires process development insights at every stage of the product lifecycle.

Q: Once you understand the customer's needs, how do you support them through the manufacturing process?

MC: Once the manufacturing process is confirmed, as Minh already mentioned, we engage a Project Manager to partner with the customer and the client's manufacturing team. The Project Manager helps coordinate the ongoing Project Timeline. By engaging a combination of Industrial Project Manager, process and commercial experts, we help our customers to develop the appropriate commercial model for their products. We also provide the appropriate commercial model for their products. We also provide the appropriate commercial model for their products.

Q: How exactly has your organization chosen to invest in cell and gene therapy manufacturing?

MC: Our new large-scale gene therapy manufacturing facility is composed of multiple production units and processes, including upstream, downstream, and fill/finish. All of the manufacturing units are built on a common, scalable, and flexible platform. This is designed to be highly adaptable to various cell and gene therapy products. We are focused on providing our customers with a scalable and flexible manufacturing process. We are focused on providing our customers with a scalable and flexible manufacturing process.

Q: What led your organization to determine that this was the right time to invest in a new gene therapy manufacturing facility?

Cell & Gene Therapy Insights | 0904 2021 | 1707

SUPPLY CHAIN: Best practices for ensuring cell and gene therapy supply chain scalability

Precisely for CGT: automating aseptic filling for lowest volumes

Cell & Gene Therapy Insights 2022: 8(3), 403–408
DOI: 10.18609/cgti.2021.059
PUBLISHED: 27 MARCH 2022

PODCAST

Barbara Fischer

Roisin McGuigan, Editor, Bioinsights, speaks to Barbara Fischer, Process Consultant, Single Use Support

...do not be afraid of digital transformation. Follow the opportunities that present themselves.

PODCAST INTERVIEW

Q: What specific trends are you seeing currently in the selection of process packaging?

BF: Customer capabilities have evolved significantly. Customers are now looking for more robust and scalable solutions. They are looking for more robust and scalable solutions. They are looking for more robust and scalable solutions. They are looking for more robust and scalable solutions.

Q: The question is: which primary packaging are suitable for all process steps and unit operations, and flexible enough to be used from early development to scale-up?

BF: The question is: which primary packaging are suitable for all process steps and unit operations, and flexible enough to be used from early development to scale-up?

Cell & Gene Therapy Insights | 0904 2021 | 405

Podcasts
in a variety
of formats and
lengths can also be
produced, either in
series or as
one-offs



Key factors to consider for successful cell therapy manufacturing: a case study

Cell & Gene Therapy Insights 2022; 8(2), 241-249
10.18609/cgti.2022.039
PUBLISHED: 2 MARCH 2022

Valentina Becherucci, Øystein Åmellem, Xavier de Mollerat du Jeu

You can listen to the [podcast at the bottom of this page](#) or read the interview below

[View pdf](#)



PODCAST INTERVIEW

QA: That makes sense. When you have a four-week manufacturing time, that means that the cells are undergoing several passages. Do you have criteria for how many passages you run in your manufacturing process, in order to not lose the cells' characteristics? Do you count the number of passages or the way you get to the desired end point of your drug?

VB: The data of all cultures comes out after process validation. The goal is to reach the therapeutic design. The culture can be shorter - you can stop it at three weeks and use four weeks. It can be more than four weeks because, according to the literature, if you culture for more than four or five weeks, you can get some unwanted effects on cells. For example, you can get genetic variation that is not good for the patient. The four weeks come from our process validation, where we produced five batches of MSCs, and in four batches we saw that the variability was low in terms of the number of cells after four weeks of culture. We also checked other parameters of MSCs, for example the antigen expression of specific markers that must be positive or negative according to International Society of Cell Therapy.

XMJ: Valentina, in this four-week process, how do you ensure you maintain sterility? Do you do weekly QC monitoring on your process?

VB: In our process, we perform initial sterility before starting the culture directly on the bioreactor. Then, we perform an in-process control of sterility after two weeks of culture, and at the end of the culture, before freezing. In our process, cells will be frozen after four weeks of culture and then moved to liquid nitrogen until you get the patient. In this case, the sterility is performed both on cells and on the cell culture media, on the equipment.

QDH: What are the QC or analytical tests you implement in your process to ensure the safety and quality of the product?

VB: According to the regulatory specification, the testing methods must be validated, and mandatory regular testing includes testing of the sterility, endotoxin, mycoplasmas, and hermesites, and in our case we also perform cell identification with flow cytometry. All these tests are performed as in-process control at different steps of the process, and also for the final release or release of the product.

QA: Valentina - as you are using flasks, you operate in Class A and culture conditions. I see you used bags, or a more closed system that you could operate in a hood?


VB: We have tested different kinds of flasks with more surface for culture. However, we do not use bags. Bags are only used in the final step for freezing and storage in liquid nitrogen. We only use open systems and flasks.

XMJ: You mentioned it is a Phase 2 process. As you move to Phase 3 and commercial, you will need to scale this process. How are you thinking about doing that?



For example:

[Key factors to consider for successful cell therapy manufacturing: a case study \(for Thermo Fisher Scientific\)](#)



VIDEO PRESENTATIONS

Our FastFacts videos are 10-15 minute edited presentations, accompanied by a poster summarising the key learning points. They are designed for the presentation of app notes, validation data, case studies, scientific posters or product demonstrations, and work well both for educational purposes and for lead generation.



Here are some examples:



A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing


Cell & Gene Therapy Insights 2021; 7(10), 389
 10.18699/igti.2021.064
 PUBLISHED: 21 APRIL 2021

FASTFACTS

Joseph O'Connor

Watch the demonstration video or read the poster for therapy manufacturing by minimizing manual touch

- ▶ Sample loading
- ▶ Activation
- ▶ Transduction or transfection
- ▶ Expansion
- ▶ Harvest



A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing (for Lonza)



Accelerating downstream analytical testing for gene therapy

Cell & Gene Therapy Insights 2022; 8(1), 23
 10.18699/igti.2022.025
 PUBLISHED: 8 FEBRUARY 2022

FASTFACTS


Harald Ehlen

Watch the video or read the poster to learn:

- ▶ The benefits of rapid, reliable in-process testing for
- ▶ How utilizing Slope Spectroscopy can remove or au
- ▶ Gene therapy case studies demonstrating use of the



Harald Ehlen has been with Repligen for 6 years of experience as Senior Pharm Biologist in QC and Analytical Development, Physiological Chemistry and then specialising in the skeletal system before moving to the



Accelerating downstream analytical testing for gene therapy (for Repligen)



Rapid Quantitation of Viral Vectors with Simple Plex Microfluidic Immunoassays

Cell & Gene Therapy Insights 2021; 7(12), 1725
 10.18699/igti.2021.267
 PUBLISHED: 20 DECEMBER 2021

FASTFACTS


Nathan Steere

Watch the video or read the poster to learn:

- ▶ Traditional immunoassays offer excellent specificity for per and can be a significant source of variability
- ▶ Simple Plex viral titration assays, run on the Ella platform, microfluidic circuits perform all reagent additions and wash
- ▶ Simple Plex assays utilize antibody reagents from industry



Nathan Steere is a Commercial Product Manager. With more than a decade of experience in the innovative laboratory technologies that facili



Rapid quantitation of viral vectors with Simple Plex microfluidic immunoassays (for Bio-Techne)



Cell and gene manufacturing: a case study approach to overcoming challenges

Cell & Gene Therapy Insights 2021; 7(2), 393
 10.18699/igti.2021.045
 PUBLISHED: 29 APRIL 2021

FASTFACTS

Sean Werner


As cell therapy manufacturing moves from translatio customers, and collaborators to better understand th

Watch the video or read the poster to learn:

- ▶ What are the biggest hurdles for cell and gene the
- ▶ What are the challenges with current technologi
- ▶ What are the biggest payoffs of solving these probl



About the speaker
 Sean Werner, President, Sexton Biotech and manufacture of cell and gene the




Cell and gene manufacturing: a case study approach to overcoming challenges (for Sexton Biotechnologies)



Our FastFacts work well for educational and lead-generation purposes

INFOGRAPHICS

Our team are experts in communicating complex scientific information via visual formats, including infographics (static, voiced and animated), PPT presentations and illustrations. They work closely with your team to define contents and style, and the resulting content can be published in *Cell & Gene Therapy Insights* or simply provided to you for your own use.



Examples include:





Voiced infographic

[Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide \(for Thermo Fisher Scientific\)](#)

Animated infographic

[Animated infographic - Regulatory FAQs & common concerns for cell & gene therapy raw and starting materials \(for Thermo Fisher Scientific\)](#)

SCIENTIFIC ILLUSTRATIONS



We work from your sketch or concept to create schematics or illustrations of your products or services

Contact Nicola McCall at n.mccall@insights.bio to discuss thought leadership and lead-generation opportunities

eBLASTS

We offer a strictly limited number of 3rd party eblasts to our registered users.

Our 2023 schedule is open for bookings. Please contact Nicola McCall at n.mccall@insights.bio.

OUR OTHER PUBLICATIONS


In addition to *Cell & Gene Therapy Insights*, BioInsights also publishes:



Immuno-Oncology Insights

Immuno-Oncology Insights is an open access, independently peer reviewed publication specifically designed to fill a number of clear and important gaps in the current slate of journals for the industrial and academic immuno-oncology communities.

Guided by an editorial board lead by Jon Wigginton and Renier J. Brentjens, *Immuno-Oncology Insights* places R&D challenges and progress across a wide variety of technology fields in context.



Vaccine Insights

Launched in 2022, *Vaccine Insights* is a peer-reviewed, open-access journal providing insights into development and manufacture of prophylactic and therapeutic vaccines. The journal brings together leading experts from pharma, biotech, academia and other key stakeholders to address critical issues and put the latest developments into context. Guided by an expert advisory board, the journal covers the most important advances in vaccine development and manufacture across all disease areas.

If you would like to distribute content to more than one of the cell & gene therapy, immuno-oncology and vaccine communities, we can promote it across multiple journals and market it to more than one set of users.